The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1099-1105

  Verrill, M W ^a   Judson, I R ^a,b   Wiltshaw, E ^a   Thomas, J M ^a   Harmer, C L ^a   Fisher, C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemotherapy; Dose intensity; Ewing's sarcoma; Primitive neuroectodermal tumour; Toxicity

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; EWING SARCOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROECTODERM TUMOR; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030665020     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008264902857     Document Type: Article

References (31)

1. Delattre O, Zucman J, Melot T et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-9.
2. Turc-Carel C, Aurias A, Mugneret F et al. Chromosomes in Ewing's sarcoma. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32: 229-38.
3. Glass AG, Fraumeni JF. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970; 44: 187-99.
4. Price CHG, Jeffree GM. Incidence of bone sarcomas in SW England, 1946-74, in relation to age, sex, tumour site and histology. Br J Cancer 1977; 36: 511-22.
5. Hayes FA, Thompson EI, Kun L et al. Ewing's sarcoma: The St. Jude experience 1978-1988. Br J Cancer 1990; 62: 327.
6. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: A 6-year experience of a European cooperative trial. Cancer 1988; 61: 23-32.
7. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-8.
8. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long term results from the first UKCCSG Ewing's tumour study (ET-1). Eur J Cancer 1997; 33: 1061-9.
9. Nesbit ME, Gehan EA, Burgert EO et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the first Intergroup study. J Clin Oncol 1990; 8: 1664-74.
10. Burgert EO, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990; 8: 1514-24.
11. Kinsella TJ, Miser JS, Triche TJ et al. Treatment of high-risk sarcomas in children and young adults: Analysis of local control using intensive combined modality therapy. NCI Monogr 1988; 291-6.
12. Craft AW, Cotterill S, Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide: A UKCCSG'MRC study. Am J Pediatr Hematol Oncol 1993; 15: S31-5.
13. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma [see comments]. J Natl Cancer Inst 1991; 83: 1460-70.
14. Smith MA. The impact of doxorubicin dose intensity on survival of patients with Ewing's sarcoma. J Clin Oncol 1991; 9: 889-91 (Letter, comment).
15. Dunst J, Sauer R, Burgers JMV et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991; 67: 2818-25.
16. Sinkovics JG, Plager C, Ayala A et al. Ewing Sarcoma: Its course and treatment in 50 adult patients. Oncology 1980; 37: 114-9.
17. Siegel RD, Ryan LM, Antman KH. Adults with Ewing's Sarcoma: An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 1988; 11: 614-7.
18. Verrill MW, Judson IR, Harmer CL et al. Ewing's sarcoma and primitive neuroectodermal tumour in adults: Are they different from Ewing's sarcoma and primitive neuroectodermal tumour in children? J Clin Oncol 1997; 15: 2611-21.
19. Craft AW. Ewing's sarcoma: United Kingdom Children's Cancer Study Group Results. Br J Cancer 1990; 62: 328-9.
20. Ambros IM, Ambros PF, Strehl S et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumours. Cancer 1991; 67: 1886-93.
21. Fellinger EJ, Garin-Chesa P, Triche TJ et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 1991; 139: 317-25.
22. Kovar H, Dworzak M, Strehl S et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990; 5: 1067-70.
23. Desmaze C, Zucman J, Delattre O et al. Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumours. Genes, Chromosomes Cancer 1992; 5: 30-4.
24. Taylor C, Patel K, Jones T et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) ising fluorescence in situ hybridisation. Br J Cancer 1993; 67: 128-33.
25. Burnet NG, Bliss JM, Harmer CL. The impact of radiotherapy dose on local control of Ewing's sarcoma of bone. Sarcoma 1997; 1: 31-8.
26. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In DeVita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: JB Lippincot 1988; 121-41.
27. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
28. Verrill M, Judson I. Jaundice with ondansetron. Lancet 1994; 344: 190-1 (Letter).
29. Skinner R, Pearson ADJ, Price L et al. Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 1989; 298: 1560-1.
30. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993; 11: 173-90.
31. Skinner R, Pearson ADJ, English MW et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996; 348: 578-80.